Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RU85053
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
RU85053 is an experimental small molecule compound (chemical formula C33H35N3O7) that acts as an inhibitor of the Proto-oncogene tyrosine-protein kinase Src. While primarily studied in the context of non-receptor protein tyrosine kinase signaling, computational drug screening studies in 2020 also identified RU85053 as a potential inhibitor of the SARS-CoV-2 RNA-directed RNA polymerase (RdRp). It has been proposed as a component of a therapeutic cocktail for COVID-19 alongside baloxavir marboxil and natamycin. Currently, the compound remains in the experimental stage with no specific commercial developer or clinical trial data publicly available.
- Other names
- RU85053RU-85053RU 85053
02
Targets
SRC (Proto-oncogene tyrosine-protein kinase Src)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on RU85053.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RU85053.